Ritsuko Komaki

Baylor College of Medicine — United States

Medicine · Health Sciences

67h-index19.3kcitations289works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(142), Lung Cancer Diagnosis and Treatment(116), Lung Cancer Research Studies(64), Esophageal Cancer Research and Treatment(58), Colorectal Cancer Treatments and Studies(43)

Publications288 total

Comparison of predicted and actual dermatitis generated from computed tomography images and dose distribution maps
Technical Innovations & Patient Support in Radiation Oncology·2024Open Access
Ridge Filter in Synchrocyclotron-Based Pencil Beam Scanning Proton Therapy System: A Study on Optimization for the Treatment of Liver Tumors
SSRN Electronic Journal·2024Open Access
Comparison of Predicted and Actual Dermatitis Generated from Computed Tomography Images and Dose Distribution Maps
SSRN Electronic Journal·2024Open Access
Data from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 12 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
TABLE 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
TABLE 3 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 9 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
FIGURE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
TABLE 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 16 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 16 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 11 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 9 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
FIGURE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 11 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Zhongxing Liao(18), Stephen G. Swisher(15), Joe Y. Chang(14), Jack A. Roth(11), Jaffer A. Ajani(11), Arlene M. Correa(11), James D. Cox(11), Ara A. Vaporciyan(9), Garrett L. Walsh(9), David C. Rice(7), Wayne L. Hofstetter(7), Wei Xiong(6), James W. Welsh(6), Pamela K. Allen(6), Walter J. Curran(5), Reza J. Mehran(5), Peter Balter(5), Steven H. Lin(5), Radhe Mohan(5), Jeffrey D. Bradley(4)